Long‐term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation

OBJECTIVES: To describe the long‐term effects of ivacaftor (Kalydeco®) in individuals with cystic fibrosis (CF) on body mass index (BMI), body composition (BC), pulmonary function (PF), resting energy expenditure (REE), and exercise capacity (EC) after ≥12 months of treatment. WORKING HYPOTHESIS: BM...

Descripción completa

Detalles Bibliográficos
Autores principales: Burghard, M (Marcella), Berkers, G (Gitte), Ghijsen, S (Sophie), Hollander‐Kraaijeveld, FM (Francis), de Winter‐de Groot, KM (Karin), van der Ent, CK (Kors), Heijerman, HGM (Harry), Takken, T (Tim), Hulzebos, HJ (Erik)
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317816/
https://www.ncbi.nlm.nih.gov/pubmed/32233113
http://dx.doi.org/10.1002/ppul.24745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317816/
https://www.ncbi.nlm.nih.gov/pubmed/32233113
http://dx.doi.org/10.1002/ppul.24745

Ejemplares similares